BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24513501)

  • 1. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
    Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
    J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: a randomized trial.
    Sarubin N; Nothdurfter C; Schüle C; Lieb M; Uhr M; Born C; Zimmermannc R; Bühner M; Konopka K; Rupprecht R; Baghai TC
    J Psychiatr Res; 2014 Jun; 53():76-83. PubMed ID: 24655586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression.
    Sarubin N; Nothdurfter C; Schmotz C; Wimmer AM; Trummer J; Lieb M; Uhr M; Baghai TC; Wetter TC; Bühner M; Rupprecht R; Schüle C
    Psychoneuroendocrinology; 2014 Jan; 39():141-151. PubMed ID: 24275013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.
    Schüle C; Baghai TC; Eser D; Zwanzger P; Jordan M; Buechs R; Rupprecht R
    Psychopharmacology (Berl); 2006 Jul; 186(4):601-11. PubMed ID: 16758243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test.
    Künzel HE; Binder EB; Nickel T; Ising M; Fuchs B; Majer M; Pfennig A; Ernst G; Kern N; Schmid DA; Uhr M; Holsboer F; Modell S
    Neuropsychopharmacology; 2003 Dec; 28(12):2169-78. PubMed ID: 12931142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
    Owashi T; Otsubo T; Oshima A; Nakagome K; Higuchi T; Kamijima K
    Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.
    Binder EB; Künzel HE; Nickel T; Kern N; Pfennig A; Majer M; Uhr M; Ising M; Holsboer F
    Psychoneuroendocrinology; 2009 Jan; 34(1):99-109. PubMed ID: 18829172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
    Nikisch G; Mathé AA; Czernik A; Thiele J; Bohner J; Eap CB; Agren H; Baumann P
    Psychopharmacology (Berl); 2005 Oct; 181(4):751-60. PubMed ID: 15988572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrinological mechanisms of actions of antidepressant drugs.
    Schüle C
    J Neuroendocrinol; 2007 Mar; 19(3):213-26. PubMed ID: 17280595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.
    Künzel HE; Ackl N; Hatzinger M; Held K; Holsboer-Trachsler E; Ising M; Kaschka W; Kasper S; Konstantinidis A; Sonntag A; Uhr M; Yassouridis A; Holsboer F; Steiger A
    J Psychiatr Res; 2009 Apr; 43(7):702-10. PubMed ID: 19038406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder.
    Schuhmacher A; Mössner R; Höfels S; Pfeiffer U; Guttenthaler V; Wagner M; Schwab SG; Maier W; Zobel A
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):237-45. PubMed ID: 20701824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?
    Ising M; Horstmann S; Kloiber S; Lucae S; Binder EB; Kern N; Künzel HE; Pfennig A; Uhr M; Holsboer F
    Biol Psychiatry; 2007 Jul; 62(1):47-54. PubMed ID: 17123470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression.
    Wichniak A; Brunner H; Ising M; Pedrosa Gil F; Holsboer F; Friess E
    Psychoneuroendocrinology; 2004 Oct; 29(9):1101-8. PubMed ID: 15219633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression.
    Bschor T; Baethge C; Adli M; Eichmann U; Ising M; Uhr M; Müller-Oerlinghausen B; Bauer M
    Depress Anxiety; 2003; 17(1):43-8. PubMed ID: 12577277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the hypothalamic-pituitary-adrenal axis and leptin levels during antidepressant treatment.
    Himmerich H; Zimmermann P; Ising M; Kloiber S; Lucae S; Kunzel HE; Binder EB; Holsboer F; Uhr M
    Neuropsychobiology; 2007; 55(1):28-35. PubMed ID: 17556850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers.
    Sher L; Oquendo MA; Burke AK; Cooper TB; Mann JJ
    J Affect Disord; 2013 Dec; 151(3):1108-12. PubMed ID: 23866302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortisol response patterns in depressed women and their healthy daughters at risk: Comparison with healthy women and their daughters.
    Gonul AS; Cetinkalp S; Tunay S; Polat I; Simsek F; Aksoy B; Kizilates G; Erdogan Y; Coburn KL
    J Psychiatr Res; 2017 Feb; 85():66-74. PubMed ID: 27837659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine.
    Schüle C; Baghai T; Zwanzger P; Ella R; Eser D; Padberg F; Möller HJ; Rupprecht R
    Psychopharmacology (Berl); 2003 Mar; 166(3):271-5. PubMed ID: 12552362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.
    Papiol S; Arias B; Gastó C; Gutiérrez B; Catalán R; Fañanás L
    J Affect Disord; 2007 Dec; 104(1-3):83-90. PubMed ID: 17467808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced suppression of adrenocorticotropic hormone and cortisol responses to hypothalamic-pituitary-adrenal function and thyrotropin-releasing hormone tests after stressful life events in patients with major depressive disorder.
    Hikichi T; Akiyoshi J; Ichioka S; Tanaka Y; Tsuru J; Goto S; Matsushita H; Hanada H; Isogawa K; Nagayama H
    Neuropsychobiology; 2007; 55(1):21-7. PubMed ID: 17556849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.